Jul 10 2007
Foamix Ltd. has announced that the Company has been selected to present at the 34th Annual Meeting of the Controlled Release Society.
A poster entitled "Bio-adhesive Vaginal Foam: In-Vitro and In-Vivo Adhesion Profile" will be presented by Foamix's CTO, Dr. Doron Friedman, at the 34th Annual Meeting of the Controlled Release Society (CRS) in Long Beach, California, US July 7-11, 2007. The abstract will also be published in CRS Journal.
Foamix accomplished its objective to be the first to develop a new type of vaginal foam vehicle. While topical formulations, such as creams, lotions, gels and ovules, are commonly used for delivery to the vaginal cavity, they are often reported to be messy, require complicated administration and can leak out after treatment, causing discomfort to the patients. Foamix's unique vaginal foam is an easy-to-use vaginal delivery system, which is simple to operate and requires minimal preparation. Vaginal foam is composed of delicate FDA approved ingredients and it is well tolerated. The foam expands gently and spreads evenly over the entire vaginal cavity surface; and it also effectively reaches the cervix. The Foamix vaginal foams are bio-adhesive, do not leak following application and thus, they can retain an active agent intra-vaginally for prolonged periods of time.
"We are excited to unveil our innovative intravaginal foam technology, and we are pleased that CRS has given us the opportunity to do so. Foam offers properties that increase usability, encourage compliance and boost user satisfaction. Our foams can effectively deliver a broad range of drugs; they are non-drip, with easy application, thus making them uniquely suitable for gynecologic application," said Foamix CEO Dr. Dov Tamarkin.